Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in ME/CFS
NCT06952413Phase 2Recruiting
- Sponsor
- National Center of Neurology and Psychiatry
- Start
- Apr 2025
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), sponsored by National Center of Neurology and Psychiatry. Started Apr 2025; status: recruiting.
02
Drugs
rituximab
03
Conditions
myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Beyond the preview
Go deeper on NCT06952413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06952413.